immunity News and Research

RSS

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.

17 May 2021

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.

17 May 2021

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

16 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

What does approval of the Pfizer vaccine for teens and preteens mean for my child?

Extending the emergency use of the Pfizer-BioNTech vaccine to preteens and young adolescents adds nearly 17 million more Americans to the pool of those eligible to be immunized against covid-19, helping to build a vaccinated population closer to herd immunity. Moderna and Johnson & Johnson are also testing the efficacy of their vaccines in teens and children.

14 May 2021

UCL scientists identify new immunotherapy to combat hepatitis B virus

Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.

14 May 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Dominance of South African SARS-CoV-2 variant in the US is unlikely but possible

Researchers in the United States and Canada have conducted a study showing that the South African variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – is unlikely to become the dominant strain in the US.

13 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

A recent report on the medRxiv* preprint server suggests that a single dose of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine could elicit higher titers of neutralizing antibodies, effectively acting as a booster dose, in people who have already been infected by the SARS-CoV-2.

13 May 2021

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.

13 May 2021

UMD receives new funding to stop infection from Lyme disease pathogens before it begins

The University of Maryland received new funding from the Steven & Alexandra Cohen Foundation to develop novel therapeutic strategies that have the potential to stop infection from Lyme disease pathogens before it begins.

13 May 2021

South Australian immunologist receives $3 million to accelerate work on Covid-19 vaccine

A leading South Australian immunologist has been awarded $3 million from the Federal Government to accelerate work on a locally developed Covid-19 vaccine, in what's anticipated to be the second line of defence against the virus.

13 May 2021

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

New research by a team at Northwestern University Feinberg School of Medicine, USA, suggests that the COVID-19 vaccine does not damage the placenta and may be safe to use during pregnancy.

13 May 2021

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Researchers in the UK have presented a multi-omics integrated blood atlas that delineates the host immune response in patients with coronavirus disease 2019 (COVID-19) of varying severity, providing a unique reference resource for the interpretation of datasets generated from interventional trials.

13 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Researchers identify six “words” used by specific immune cells to call up immune defense genes

UCLA life scientists have identified six "words" that specific immune cells use to call up immune defense genes -- an important step toward understanding the language the body uses to marshal responses to threats.

13 May 2021

AI helps assess patient's risk of regenerative outcomes after treatment of peri-implantitis

Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.

12 May 2021

immunity News and Research

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

What does approval of the Pfizer vaccine for teens and preteens mean for my child?

UCL scientists identify new immunotherapy to combat hepatitis B virus

A look at how coronavirus disease (COVID-19) affects Parkinson's

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

Dominance of South African SARS-CoV-2 variant in the US is unlikely but possible

Antibodies generated by malaria cross-react with SARS-CoV-2

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

UMD receives new funding to stop infection from Lyme disease pathogens before it begins

South Australian immunologist receives $3 million to accelerate work on Covid-19 vaccine

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers identify six “words” used by specific immune cells to call up immune defense genes

AI helps assess patient's risk of regenerative outcomes after treatment of peri-implantitis

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News